Search
Clomifene
go.drugbank.com/drugs/DB00882ApprovedInvestigationalA triphenyl ethylene stilbene derivative which is an estrogen agonist or antagonist depending on the target tissue.
CR665
go.drugbank.com/drugs/DB05155ExperimentalIn preclinical studies, CR665 was highly selective for the peripheral kappa opioid receptor. Preclinical animal studies suggest that CR665 is a potent analgesic compound.
Cositecan
go.drugbank.com/drugs/DB05806InvestigationalCositecan is the novel camptothecin derivative which is also known as Karenitecin. It has been developed for superior oral bioavailability and increased lactone stability. It is used to treat cancer.
Antihemophilic factor (recombinant), PEGylated
go.drugbank.com/drugs/DB09329ApprovedInvestigationalAntihemophilic Factor (Recombinant), PEGylated, was approved by the FDA in December 2016 as the product _Adynovate_ [FDA label]. … It has been created to increase the half-life of factor VIII, which decreases dose frequency and decreases the occurrence of bleeding events [A32067], [A32069], [FDA label].
Sipuleucel-T
go.drugbank.com/drugs/DB06688ApprovedInvestigationalSipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. … In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation.
Crotalus atrox antivenin
go.drugbank.com/drugs/DB13892ApprovedCrotalus atrox antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus atrox (Western Diamondback rattlesnake).
Glutathione
go.drugbank.com/drugs/DB00143ApprovedInvestigationalNutraceuticalA tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.
Selpercatinib
go.drugbank.com/drugs/DB15685ApprovedInvestigational[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[A239249] Surgical interventions such as partial external bile diversion and ileal exclusion have also been used as treatments. … It was granted FDA approval on 29 September 2021.
Lipegfilgrastim
go.drugbank.com/drugs/DB13200ApprovedLipegfilgrastim, previously known as XM22, is a pegylated, recombinant granulocyte colony-stimulating factor (G-CSF) that was synthetized using a highly site-specific glycoPEGylation technology [A32665 … It is used as an alternate to [DB00019] for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropenia.